Vaccibody with vaccination of first patient

Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16).

 

Patients will receive intramuscular vaccinations of VB10.16 at three different time points. Two different dosing schedules will be evaluated during the first phase of the study in patients diagnosed with CIN 2, the best vaccination schedule will then be evaluated in the second phase in both CIN 2 and CIN 3 patients.

The primary objective of the study is to evaluate the safety and tolerability of three doses of 3 mg VB10.16. The secondary objectives are to assess T cell mediated immune responses in the peripheral blood as well as in the pre-malignant tissue of the CIN 2/3 lesions and to evaluate early signs of efficacy by means of HPV clearance and CIN regression.

Martin Bonde, CEO of Vaccibody, commented: We are pleased to announce commencement of patient treatment in this first clinical trial with Vaccibody’s lead product VB10.16. Surgery is currently the only available therapy to remove abnormal cervical lesions caused by human papillomavirus and thereby stop the progression to cervical cancer. We are hopeful that VB10.16 immunotherapy can help change this treatment paradigm by offering a safe and efficacious alternative in the form of a therapeutic HPV vaccine.

Principal investigator,  Prof. Dr. med. Karl Ulrich Petry, Department of Obstetrics & Gynaecology Klinikum Wolfsburg commented:  The scientific approach of this well designed clinical study offers the chance to get a thorough understanding on how patients respond to VB10.16 immunotherapy. The first dosing of a patient has just been performed successfully in our hospital . We are convinced that patients with CIN 2 and CIN 3 will be very motivated to participate in the study to test this therapeutic vaccination as it might offer a non-invasive treatment option avoiding the side effects associated with surgical excision of the affected tissue and potentially also cure the underlying HPV infection and prevent recurrence. Furthermore, VB10.16 could also protect from other HPV16 induced cancers.

 

About VB10.16

The company’s lead product, VB10.16, is a therapeutic DNA vaccine developed to treat human papillomavirus type 16 (HPV16) induced pre-malignancies and malignancies.

About Cervical Intraepithelial Neoplasia (CIN) and Cervical Cancer

Per year approximately 530,000 women are diagnosed with cervical cancer worldwide and over 275,000 women die of the disease annually. Invasive cervical cancer is preceded by a long phase of pre-invasive disease called Cervical Intraepithelial Neoplasia (CIN). Globally the number of high grade lesions (CIN 2/3) the immediate precursors to malignancy, is estimated to be in the range of 10 million.

Virtually all cervical cancers are caused by high risk HPV types. Among the different high risk HPV types known, HPV16 has been reported to be the most common genotype in high grade cervical intraepithelial neoplasia. It can be detected in up to 60 % of all cervical cancers, especially in younger women and it has also been found to play an essential role in the development of several other cancer types (approximately 90% of anal cancers; 40% of penile, vaginal, and vulvar cancers; 25% of oral cavity cancers and 35% of oropharyngeal cancers).

Current standard therapy for CIN 2/3 varies between countries and regions and often involves surgical removal of the affected tissue. These invasive procedures are associated with bleeding, infection, cervical stenosis, scarring and most importantly pre-term deliveries in subsequent pregnancies. As a result, there is a significant need for an effective therapeutic vaccine to treat existing HPV infection and associated pre-malignancies and malignancies of the cervix and thereby prevent the development of cervical cancer caused by human papillomavirus.

About Vaccibody AS

Vaccibody is a biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody’s lead program is focused on VB10.16, a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study will evaluate the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

 

 

 

Inven2 with broad immuno-oncology portfolio

NNV_bilde

Oslo Cancer Cluster member Inven2 is the largest technology transfer company in the Nordic region and a leading actor within Life Science. Oslo University Hospital and the University of Oslo are pioneers in several areas of immunology and cell based cancer therapies. Due to this, Inven2 has a broad portfolio within immuno-oncology to offer.

Immuno-oncology is one of the hottest topics globally at the time. Cancer immunotherapy, as this field is also called, was voted the “Science breakthrough of the year for 2013″ and qualified as “one of the world’s top disrupters” by Goldman Sachs in 2013. Cancer immunotherapy was also the “hot-topic” at the 2014 American Association for Cancer (AACR) meeting where the various current approaches and strategies being advanced today were well represented.


Portfolio of both immuno-oncology therapies and methods

Ongoing innovation projects within immuno-oncology at Oslo University Hopsital and the University of Oslo counts 6 therapies and 8 different technologies/methods being explored. Please see a full list below:

Immune-Oncology-2015_01-print

 

If you want to know more about these projects, please contact Jonny Østensen, Vice President Technology: jonny.ostensen@inven2.com / +47 911 922 36

PCI Biotech signs research collaboration with top-10 large pharma company

Doctor and nurse assessing the treatment of a cancer patient.

Oslo Cancer Cluster member PCI Biotech has signed an agreement with an undisclosed top-10 large pharma company, with the aim to evaluate synergistic effects of the PCI technology with their therapeutic nucleic acid technology. Initially, the purpose of the pre-clinical research program is to determine whether PCI has the potential to enhance the therapeutic effect of their nucleic acid technology platform.

The current pre-clinical research agreement covers evaluation of technology compatibility and synergy based on in vitro studies. The costs related to the research collaboration will be covered by the pharma company, which is one of the global leaders in nucleic acid therapeutics. The companies will evaluate the data generated in this research collaboration and based on this explore the potential for a further partnership. The original evaluation period spans over 9 months, but may be further extended.

“I’m delighted to announce this research agreement with one of the largest pharma companies in the world. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities, including cancer immunotherapy and mRNA therapeutics. This agreement shows that external players share this view”. Per Walday, CEO.

 

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.

The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com

PCI Biotech announces activation of Oslo University Hospital as a new clinical site

PCI Biotech has activated Oslo University Hospital as a new clinical site in the phase I/II study of Amphinex in patients with inoperable bile duct cancer, cholangiocarcinoma.

Principal Investigator at Oslo University Hospital, Dr. Svein Dueland, said: “Bile duct cancer is a devastating disease lacking good treatment options for a majority of the patients. PCI of gemcitabine with Amphinex is an innovative treatment concept that could potentially give significant local tumour response in these patients. I look forward to working on this study, which is well designed to demonstrate a potential clinical benefit of Amphinex induced PCI of gemcitabine in bile duct cancer patients.”

Per Walday, CEO of PCI Biotech, said: “I’m delighted with the activation of Oslo University Hospital as a contributing site for this study.  The PCI technology originates from this hospital and it will be a pleasure to work closely with these highly competent investigators to progress the study as quickly as possible. Bile duct cancer has a high need of new local treatment options and the specific attributes of the PCI technology fits well with this disease and its unmet medical need.”

 

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange (Axess). The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI technology works by inducing triggered endosomal release and may be used to unlock the true potential of a wide array of therapeutic modalities, such as small molecules, vaccines and nucleic acids.

The company currently has a bile duct cancer program in phase I/II clinical development. Bile duct cancer is an orphan indication without any approved medicinal products and a high medical need for better local treatments. It is an indication well suited for PCI treatment, with easy light access for intraluminal surface illumination through routine endoscopic methods and an active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction technology for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI significantly increases the number of activated antigen-specific CTLs by enhancing the MHC I antigen presentation of antigen presenting cells. When applied in the emerging field of cancer immunotherapy, PCI can be used to enhance the important cytotoxic effect of therapeutic cancer vaccines.

PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com

NLSDays 2015: Meet international life science leaders and discuss the sector’s future at the Nordic region’s largest partnering meeting

NLSDays September 9-10 at Stockholm Waterfront is the Nordic region’s premier life science event. The global life science sector is undergoing major structural changes, and as part of a strong established hub, companies in Sweden and the Nordic countries are of great interest when international investors and corporations are looking for new partners.

The entire value chain from basic research to the introduction of new therapies is subject to transformation – not least due to rapid developments in digital health. Life science companies therefore need to find new ways to collaborate and fund their projects. Since the Nordic region offers a modern, competitive environment for academia and research companies alike, the region has become highly attractive for the global life science industry.

  • NLSDays has become the most important meeting place for global investors and corporations that are looking for new collaborations in the Nordic region. The event is on course for record numbers and deals such as the recent one between Alligator Bioscience and Janssen Biotech which illustrates that Swedish companies offer major value to partners, says Jonas Ekstrand, CEO SwedenBIO, the Swedish national life science industry organization which founded the event three years ago.

Overall, the life science sector is currently very active in the Nordic countries. For example, the Oslo Cancer Cluster Innovation Park, an investment of around 100 million Euros opens today (24 August). Furthermore, AstraZeneca recently announced a Euros 260 million investment in a new plant for bio-pharmaceutical production and from January 2014, 18 life science companies across all subsectors from medtech to biopharma have been listed on Nasdaq Nordic at a combined value of about Euros 250 million (Source Nasdaq). Furthermore, initiatives and companies in new areas such as personalized medicine, digital health and outcomes based provision are emerging at an accelerating pace.

During Nordic Life Science Days 2015 the main theme is “The New Value Chain”. The 2 day program covers several sessions in which international life science leaders will discuss strategies on how new partnerships can be established and how medical research and the life science industry in the Nordics can contribute.

Super Sessions from the program:

  • International Investors (9 September at 11.30 – 12.30)

International life science investors talk about their investment models and what they look for from entrepreneurs.

  • Personalized Healthcare – Matching Medicines to Patients (September 10 at 08:45 – 09-45)

How will big data and new diagnostic methods impact the future of medical research and treatment modalities? Listen to how the Digital Doctor Watson can revolutionize health care.

  • Oncology 2025 (10 September 11.30 – 12.30)

Immuno-oncology is hotter than ever and there is an ongoing competition between the big global companies to take on the most promising projects. Representatives from several of the major players talk about their strategies.

Currently, 800 delegates are registered for this year’s NLSDays, which is 33% more than at the corresponding time last year. This strongly indicate that the meeting will attract over 1,000 participants, outnumbering last year’s number of delegates.

The conference is organized September 9-10, 2015 at Stockholm Waterfront Congress Centre, Nils Ericssons Plan 4 in Stockholm. More info on www.nlsdays.com.

 

About NLSDays

Founded in 2012 the Nordic Life Science Days has grown rapidly to become the largest Nordic partnering conference for the global life science industry. In 2014, 890 delegates from 28 countries attended the meeting. The 580 companies attending offered 490 licensing opportunities in the partnering system and during the two days 1600 one-on-one meetings were scheduled. Among the investors and big pharma already registered for the meeting in September 2015 are AbbVie, Alexion, Almi Invest, Astellas, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Cadila Pharma, Johnson & Johnson, HealthCap, Industrifonden, Karolinska Development, Merck-MSD, Novartis, Pfizer, Pierre Fabre, P.U.LS. AB, Recipharm, Roche, Seventure Partners, SR-One.

In addition to partnering, NLSDays also offers an exhibition and a seminar program with 10 super session and four topic specific workshops. Speakers include senior representatives from the global life science companies, investors, and academic leaders who will all share their expertise and views for the future.

About SwedenBIO

SwedenBIO who is the founder and organizer of the Nordic Life Science Days is the Swedish life science industry organization. Our nearly 200 members operate across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves to the benefit the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to improve the conditions for the life science industry for the benefit of industry growth and business development.

 

Oslo Cancer Cluster Incubator filling up

12 companies will have offices and lab in Oslo Cancer Cluster Incubator from August on. Bjørn Klem, General Manager of the Incubator, anticipates full house by January 2016.

– If each and every company we have given a quote so far, accepts, we actually are over booked. As of now, we have a good mix of companies. We look forward to have even more start-ups as a result of the activity in Oslo Cancer Cluster Innovation Park and the increased focus on commersialization of cancer research the building represents, says Klem.

The companies will start moving into the Incubator the first week of August, and from then on it is business 24/7. The Oslo Cancer Cluster Managament Team will support the incubator companies with competence within business development, communication, partnering, investor contacts and so on thorugh Oslo Cancer Cluster´s extensive network.

 

Overview Oslo Cancer Cluster Incubator companies as of mid-June:
See profiles of the companies on the Oslo Cancer Cluster Incubator website

  • DNB
  • Curida
  • Intersint
  • Ultimovacs
  • Inven2
  • Lifandis
  • Medivir
  • Pharmalink
  • Normetrix
  • Lytix Biopharma
  • Radium Hospital Research Foundation
  • Oslo Cancer Cluster Management Team

 

 

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology and contemplate a private placement of NOK 125–150 million to fund the combined business

Tagovax has entered into an agreement with the shareholders of Oncos Therapeutics to acquire the shares of Oncos with settlement in Targovax shares. The combined company with multiple assets in research and development will be a Nordic leader within immuno-oncology. The new company will have a strong senior management team and be financially backed by reputable institutional investors with sector specialist HealthCap as the largest shareholder.

To fund the combined company, Targovax contemplates to raise NOK 125-150 million through a private placement directed towards Norwegian and international investors, and has already received indications from leading institutional investors for a substantial amount, including but not limited to a NOK 26 million commitment from HealthCap, NOK 25 million from Datum Invest AS and NOK 5 million from the Norwegian Radium Hospital Research Foundation. In addition, the Private Placement is directed towards the 24 employees of Targovax and Oncos and their respective subsidiaries, and companies controlled by any such employees.

 

Rationale for the Transaction

Targovax and Oncos—based in Oslo and Helsinki, respectively—are both clinical-stage biotechnology companies with broad pipelines addressing the immuno-oncology market, which currently is quite modest, but is expected to grow to USD 30-35 billion over the next decade.

By combining Targovax and Oncos, a larger and more visible Nordic immuno-oncology player with a more extensive portfolio will be created. Furthermore, the combination of two highly competent and complementary organizations will promote more efficient execution and accelerate the development of ongoing and future programs.

Clinical results to date confirm the safety and the mechanisms of action for both technology platforms. Safety data from Targovax and Oncos programs have been collected on approximately 250 and 290 patients, respectively. Both companies have completed Phase I and are now in Phase II development, or about to enter Phase II development, with broad pipelines, and both utilize an immuno-oncology approach that is highly suitable for combination therapies. Clinical programs in several indications will provide increased opportunities for newsflow over the next 18 months.

“The combination of Targovax and Oncos creates a major Nordic player within immuno-oncology. We will have a wide array of programs in the pipeline and multiple shots at goal. The companies’ complementary technologies will provide a unique platform for the development of cutting-edge immunotherapies, and we will have a higher chance of success, thus offering investors an even more compelling opportunity. I am excited to lead an organization of highly skilled professionals with deep industry experience”, said Gunnar Gårdemyr, Chief Executive Officer of Targovax.

 

Senior Executives and Board of Directors

After the Transaction, the highly experienced senior management team will consist of the following members:

  • Gunnar Gårdemyr (Chief Executive Officer) has more than 30 years of international experience in the pharmaceutical and biotech industry from companies such as Nycomed and Takeda
  • Magnus Jäderberg (Chief Medical Officer) has more than 25 years of experience from R&D functions and was previously CMO at Bristol-Myers Squibb (Europe)
  • Øystein Soug (Chief Financial Officer) has prior experience as the Chief Financial Officer of Algeta and in positions with the Orkla Group
  • Jon Amund Eriksen (Chief Operating Officer) was the co-founder of Targovax and has 35 years of R&D experience in the pharmaceutical and biotech industry, of which 25 years were within immuno-oncology

After the Transaction, the proposed Board of Directors will consist of the following members:

  • Jónas Einarsson (Chairman of the Board of Directors), Chief Executive Officer of the Norwegian Radium Hospital Research Foundation
  • Johan Christenson (Board Member), Partner at HealthCap
  • Per Samuelsson (Board Member), Partner at HealthCap
  • Lars Lund-Roland (Board Member), CEO of Bringwell, with more than 25 years of experience from various executive positions within Merck
  • Bente-Lill Romøren (Board Member), Board Member of the Norwegian Radium Hospital Research Foundation and Chairman of Farmastat and Photocure
  • Robert Burns (Board Member), Chairman of Haemostatix, previously CEO of 4-Antibody, Affitech, and Celldex Therapeutics, all three being early companies in the immuno-oncology space

 

The Transaction and the Private Placement

Targovax has entered into an agreement with the shareholders of Oncos to acquire the shares of Oncos with settlement in Targovax shares. After completion of the Transaction, the shareholders of Oncos will own 50 per cent of the combined company. The shareholders of Oncos will in aggregate receive 9,429,404 new Targovax shares that are to be issued at NOK 25.00 per share.

Targovax further contemplates to raise NOK 125-150 million in equity through the Private Placement to fund the combined business. The subscription price in the Private Placement is set to NOK 25.00 per share. The application period commences today on 11 June 2015 at 09:00 (CET) and will close on 19 June 2014 at 16:00 hours (CET). The Company, together with the Joint Global Coordinators (as defined below), reserve the right to close the application period at any time at their sole discretion, at short notice. The minimum order size and allocation in the Private Placement has been set to offer shares worth the NOK or share equivalent of EUR 100,000. The minimum order size and allocation amount does not apply to Eligible Employees. The allocation of shares will be determined at the end of the application period. The final allocation will be made at the Board’s sole discretion.

An updated presentation of the Company and the Transaction is available on the Company’s web site, www.targovax.com.

ABG Sundal Collier, Arctic Securities and DNB Markets are acting as Joint Global Coordinators and Bookrunners for the Private Placement (the “Joint Global Coordinators”). DNB Markets has acted as financial adviser to Targovax in relation to the Transaction. Guggenheim Securities, LLC has acted as financial adviser to Oncos in relation to the Transaction.

 

About Targovax
Targovax is an Oslo-area based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers. Established in 2010 by the inventors of this RAS-targeted technology and the Norwegian Radium Hospital Research Foundation in Oslo, Targovax has over 25 years of direct experience and has seen more than 250 patients treated with this promising technology.

 

About Oncos
Oncos is a privately funded clinical-stage biotechnology company focused on the development and commercialization of targeted cancer immunotherapy. Oncos’ product candidates induce a tailored response by the immune system directed at each patient’s unique cancer cells. Oncos’ lead product candidate, ONCOS-102, has successfully completed Phase I clinical studies. Additionally, a promising pipeline has been developed using Oncos’ patented adenovirus-based cancer immunotherapy platform, for the treatment of several cancer types, including soft tissue sarcoma, ovarian cancer and mesothelioma. The novel immunotherapy platform is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes.

 

 

Vaccibody aquaculture collaboration granted 10 MNOK

News4

The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 Million through the Norwegian Research Council’s program Biotek2021. Oslo Cancer Cluster member Vaccibody is a partner in the project together with The Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and Kongla AS. 

 

The purpose of the project is to develop customized targeted fish vaccines based on the Vaccibody principle.  The NOK 10 million will be awarded over 3 years.

Tom Pike, Chairman and Acting CEO of Vaccibody, commented: “We are very pleased to be a part of this collaboration and for the funding it will receive from the Norwegian Research Council .The fish farming industry are facing a number of challenges related to infections and the Vaccibody technology is well suited to attack these challenges in a sustainable manner, without the global issues associated with antibiotics. We are also proud to work with a consortium of well qualified partners.  The project fits well with Vaccibody’s strategy to develop its technology platform together with partners while focusing the main share of its internal resources on the development of VB10.16, a therapeutic DNA vaccine to treat precancerous lesions of the cervix currently entering Phase I/IIa.”

 

About Vaccibody AS

Vaccibody is a biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines which target cancer and infectious diseases, for human and veterinary use. Vaccibody’s lead drug candidate VB10.16 is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The company is currently entering it’s first-in-man study that will evaluate the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).

NLS Days – time to sign up

Oslo Cancer Cluster is one of the supporting organizations for this years Nordic Life Science Days in Stockholm. Members of the cluster benefit from special rates on participation plus we host an Oncology 2025 Super Session.

In collaboration with LMI, Nansen Neuroscience Network and other healthcare industry actors in Norway, Oslo Cancer Cluster will attend NLSDays to promote Norwegian Healthcare Industry and the cluster members.

Questions regarding the conference may be directed to Jutta Heix, International Advisor or Elisabeth Kirkeng Andersen, Head of Communicaton.

Read the latest newsletter from NLSDays 2015 below or online

The 3rd annual Nordic Life Science Days partnering conference will take place September 9–10 in Stockholm, Sweden, at the Waterfront. NLSDays Super Sessions and Workshops feature top industry leaders and executives speaking on relevant trends to industry decision makers.


Already 50+ Company Presentations confirmed

Presenting at NLSDays is the perfect chance to increase your visibility and attract more partners. Pitch your company’s profile, strategy and objectives to a global audience. Be seen by BD executives, investors, analysts, media and get more activity in partneringONE®. Still a few 6mn and 12mn available slots, don’t miss the opportunity to book your presentation when registering.


Already 50+ Exhibitors confirmed
NLSDays brings hundreds of Life Science Industry leaders from 30+ countries together for 2 days of intensive networking. As an exhibitor, you will reach high-level executives and influential decision makers who come to NLSDays to meet with new players in the industry and initiate partnerships. Still a few 4sqm, 6sqm and 9sqm available stands, don’t miss the opportunity to book yours now.


Oncology 2025 Super Session
Hosted by Oslo Cancer Cluster. Oncology is at the forefront of realizing the promises of precision medicine. Huge and complex datasets are exploited for novel drugs devolpment as well as for informed and real-time care decisions. Emerging cancer immunotherapies represent a paradigm shift for cancer treatment triggening a global R&D race and novel partnerships. Furthermore, the convergence of the genetics and digital revolution creates novel types of products, companies and growth opportunities transforming the sector.


International Investors Super Session

Hosted by Business Sweden, co-hosted by Industrifonden and HealthCap. Meet the investors actively investing in European Life Sciences companies. What are they looking for? What are the learnings in biotech and medtech investing over the past decade? How are these learnings being applied in current investments decisions? How is the financial climate in Life Sciences today?


Member of a supporting organization?
Since Oslo  Cancer Cluster is a supporting organization, members get a discount. Send an e-mail to Elisabeth Kirkeng Andersen, Head of Communicaton to get the Promotion Code and benefit from discount on all registration fees. Remember that Regular Rate registration period ends on June 30, 2015.


Interested in
sponsoring, exhibiting, presenting ? Contact: Olivier Duchamp, olivier.duchamp@bionordic.org

Large Oslo Cancer Cluster delegation to BIO2015

More than 15 Oslo Cancer Cluster members will be present at BIO2015 in Philadelphia in June. BIO is the world´s largest biotech fair and a very important partnering event for the cluster.

The companies attending BIO from the cluster are: BerGenBio, Lifandis, Lytix Biopharma, Nextera, Nordic Nanovector, Normetrix, Pharmalink Oncology, Inven2, BTO, Targovax, Ultimovacs, Vaccibody, The Radium Hospital Research Foundation, Chiltern and DNB Healthcare.

International Advisor Jutta Heix will represent Oslo Cancer Cluster Managment Team.

International Cancer Cluster Showcase
Oslo Cancer Cluster will also this year arrange International Cancer Cluster Showcase at BIO, together with other world-leading cancer clusters.  New partners are OBN, UK with a strong international investor network and the Wistar Institute from Philadelphia as local partner.

Member companies pitching at the International Cancer Cluster Showcase are Inven2, Ultimovacs and Nordic Nanovector.

Inven2, Norway´s largest TTO, will pitch their portfolio of early projects which is really strong in immuno-oncology, Ultimovacs will present the clinical development of their universal cancer vaccine, whilst Nordic Nanovector will present the clinical development of their targeted radiopharmaceutical treatment of lymphoma. Nordic Nanovector went public this March with one of the biggest IPO´s in European biotech so far this year.

We are very proud to have two Oslo Cancer Cluster members sponsoring the International Cancer Cluster Showcase this year: Chiltern and DNB Healthcare.

DNB Healthcare is also hosting a special healthcare event in New York on June 12 prior to BIO.